ClinicalTrials.gg
Not yet recruitingNCT07282509Updated Dec 15, 2025

Safety and Efficacy of Paclitaxel Liposome Arterial Infusion Combined With Systemic Therapy for Second-Line Treatment of Advanced Liver Cancer

A Phase 1/2 interventional study of HA131 and Enlonstobart Injection in Advanced Hepatocellular Carcinoma (HCC), sponsored by CSPC ZhongQi Pharmaceutical Technology Co., Ltd.. Not yet recruiting. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-12-15.

Sponsored by CSPC ZhongQi Pharmaceutical Technology Co., Ltd. (part of CSPC Pharmaceutical Group Limited) · Phase 1/2, Interventional, and Treatment

How we know · 10 judgments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
116
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This trial is an open-label, dose-escalation, and randomized controlled Phase Ib/II clinical study for second-line treatment in participants with advanced hepatocellular carcinoma (HCC). Its primary objective is to evaluate the safety, tolerability, pharmacokinetic profiles, and efficacy of transcatheter arterial infusion of HA131 combined with systemic therapy in the second-line treatment of participants with advanced HCC.

02

Conditions studied

  • Advanced Hepatocellular Carcinoma (HCC)
03

In context

Carcinoma, Hepatocellular

3,653 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,065 are open to participants now.

This study's planned enrollment of 116 is above the median of 53 across 2,621 interventional studies indexed under Carcinoma, Hepatocellular.

Browse Carcinoma, Hepatocellular studies →

Lead sponsor

CSPC ZhongQi Pharmaceutical Technology Co., Ltd. is the lead sponsor of 167 studies on the registry; 47 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1.Aged 18 to 75 years (inclusive), regardless of gender;
  • 2.Diagnosed with hepatocellular carcinoma (HCC) by histopathology, cytology, or imaging;
  • 3.HCC classified as B/C stage per BCLC (Barcelona Clinic Liver Cancer) staging system, or IIb/IIIa/IIIb stage as defined in Clinical Practice Guidelines for Primary Liver Cancer (2024 Edition) (organized by the Guidelines Committee of the Chinese Society of Clinical Oncology, 2024);
  • 4. liver function class ≤ 7 points within 7 days prior to the first dose administration;
  • 5.Progressive disease after prior systemic antineoplastic therapy containing /PD-L1 monoclonal antibody;
  • 6.At least one at the hepatic arterial infusion site per (Response Evaluation Criteria in Solid Tumors) Version 1.1 (lesion longest diameter ≥ 1 cm; lesions that have not received prior local therapy, or lesions that progressed again after local therapy);
  • 7. (Eastern Cooperative Oncology Group) Performance Status (PS) score: 0-1.
  • 8.Controlled hypertension, with blood pressure ≤ 150/90 mmHg and no changes to the antihypertensive regimen within one week prior to screening;
  • 9.Estimated survival time of more than 3 months;
  • 10.Before randomization, major organ/system functions are basically normal, meeting the criteria as assessed by laboratory tests.
  • 11.Eligible individuals of (both males and females) must agree to use reliable methods (hormonal contraceptives, barrier methods, or abstinence) with their partners during the trial and for at least 6 months after the last dose; female individuals of childbearing age must have a negative serum pregnancy test within 7 days before enrollment;
  • 12.Participants must be informed about the study prior to the trial and voluntarily sign a written form.

Exclusion criteria

Exclusion Criteria:

  • 1. confirmed fibrolamellar hepatocellular carcinoma (HCC), sarcomatoid HCC, cholangiocellular carcinoma, or combined hepatocellular-cholangiocarcinoma;
  • 2.History of liver surgery and/or local treatment for HCC within 4 weeks prior to the first dose;
  • 3.Previous antineoplastic treatment with lenvatinib;
  • 4.Use of traditional Chinese medicine (TCM) preparations with indicated efficacy for anti-HCC within 14 days prior to the first dose; having received within 28 days prior to the first dose.
  • 5.Active , , or uncontrolled spinal cord compression;
  • 6.Adverse reactions from previous antineoplastic treatment that have not resolved to ≤ Grade 1 per Version 5.0 (except for toxicities such as alopecia that are deemed to pose no safety risks by the investigator);
  • 7. to transcatheter arterial infusion interventional surgery; known contraindications or severe allergic reactions to any component of lenvatinib, PD-1/PD-L1 monoclonal antibody, paclitaxel, or cationic liposomes;
  • 8.Malabsorption syndrome or inability to take oral medications due to other reasons;
  • 9.Need for administration of strong inducers or strong inhibitors of CYP2C8 and within 2 weeks prior to the first study treatment or during the treatment period;
  • 10.Active infection within 2 weeks prior to the first dose; presence of peripheral neuropathy of Grade II or higher (per NCI-CTCAE Version 5.0);
  • 11.History of disease, immunodeficiency, other acquired or congenital immunodeficiency diseases, or current use of ;
  • 12.Untreated active .
  • 13.Participants positive for anti- virus antibody (HCV-Ab) with HCV-RNA level above the lower limit of the central laboratory's detection range;
  • 14.Participants with active syphilis;
  • 15.A history of past or current hepatic encephalopathy;
  • 16.Presence of ascites detectable on physical examination, ascites causing clinical symptoms, or ascites requiring special management during screening. Uncontrolled pleural effusion or pericardial effusion during screening;
  • 17.Active gastrointestinal bleeding or a documented history of gastrointestinal bleeding within 6 months before the first dose; history of gastrointestinal perforation and/or fistula, or history of gastrointestinal obstruction within 6 months before the first dose;
  • 18.History of major surgery within 4 weeks before the first dose (procedures such as central venous catheterization, needle , and feeding tube placement are not considered major surgery);
  • 19.History of solid organ or hematopoietic stem cell transplantation;
  • 20.Past or current non-infectious pneumonia/interstitial lung disease requiring systemic treatment;
  • 21.Cardiac dysfunction, including:

    1. Diagnosis of long syndrome, or QTcF (corrected QT interval using Fridericia's formula) ≥ 450 ms in males and ≥ 470 ms in females during screening (only one recheck is permitted during screening, with the result of the last ECG in the screening period taken as final);
    2. High-grade atrioventricular block;
    3. Malignant arrhythmia poorly controlled by medication;
    4. History of chronic heart failure with (New York Heart Association) functional class ≥ 3;
    5. Severe valvular heart regurgitation or stenosis requiring treatment;
    6. Acute coronary syndrome or severe myocardial disease (including primary cardiomyopathy and other severe myocardial diseases assessed by the investigator) within 6 months prior to screening; severe pericardial disease (including acute pericarditis, constrictive pericarditis and other severe pericardial diseases assessed by the investigator) within 6 months prior to screening;
    7. (LVEF) \< 50% as indicated by echocardiography;
  • 22.History of severe neurological or psychiatric disorders (including epilepsy or dementia) that affect trial compliance;
  • 23.Limb vascular thrombosis with potential severe consequences detected by ultrasound during screening; or history of thromboembolic events within 12 months prior to enrollment;
  • 24.Participants with severe bleeding tendency, or history of major bleeding events within the past 6 months (e.g., previous intracranial hemorrhage, gastrointestinal bleeding, or purpura);
  • 25.Urinary protein ≥ 1 g/24 h. Participants with proteinuria > 1+ on urinalysis will undergo 24-hour urine collection for quantitative assessment of proteinuria;
  • 26.Other conditions deemed by the investigator to potentially increase participant risk or interfere with trial results.
Terms in these criteria, in plain language(25)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
116 participants (estimated)

Study arms

  • Experimental
    Phase Ib Cohort 1

    Lenvatinib combined with elonstobart.

    Drug: Enlonstobart Injection · Drug: Lenvatinib Mesilate Capsules

  • Experimental
    Phase Ib Cohort 2

    Transcatheter arterial infusion of HA131 combined with systemic therapy (lenvatinib with pembrolizumab).

    Drug: HA131 · Drug: Pembrolizumab Injection · Drug: Lenvatinib Mesilate Capsules

  • Experimental
    Phase Ib Cohort 3

    Transcatheter arterial infusion of HA131 combined with systemic therapy (lenvatinib with elonstobart )

    Drug: HA131 · Drug: Enlonstobart Injection · Drug: Lenvatinib Mesilate Capsules

  • Experimental
    Phase II Experimental Arm

    Transcatheter arterial infusion of HA131 combined with systemic therapy (lenvatinib with or without elonstobart ).

    Drug: HA131 · Drug: Enlonstobart Injection · Drug: Lenvatinib Mesilate Capsules

  • Active comparator
    Phase II Control Arm

    Systemic therapy alone (lenvatinib with or without elonstobart ).

    Drug: Enlonstobart Injection · Drug: Lenvatinib Mesilate Capsules

Interventions

06

What researchers measure

Primary outcomes

  1. Phase Ib-DLT

    Incidence of Dose-Limiting Toxicity

    Time frame: 3years

  2. Phase Ib- AE

    Adverse Event

    Time frame: 3years

  3. Phase II- ORR

    Overall Response Rate

    Time frame: 3years

Secondary outcomes

  1. Phase Ib- ORR

    Overall Response Rate

    Time frame: 3years

  2. Phase Ib- DCR

    Disease Control Rate

    Time frame: 3years

  3. Phase Ib- DoR

    Duration of Response

    Time frame: 3years

  4. Phase Ib- TTR

    Time to Response

    Time frame: 3years

  5. Phase Ib-PFS

    Progression-Free Survival

    Time frame: 3years

  6. Phase Ib- OS

    Overall Survival

    Time frame: 3years

  7. Phase Ib-PK:plasma concentration of Paclitaxel, DOTAP, Enlonstobart

    Pharmacokinetics:plasma concentration of Paclitaxel, DOTAP, Enlonstobart

    Time frame: 3years

  8. Phase Ib- ADA

    Anti-Drug Antibodies

    Time frame: 3years

  9. Phase Ib- Nab

    Neutralizing Anti-Drug Antibodies

    Time frame: 3years

  10. Phase II- PFS

    Progression-Free Survival

    Time frame: 3years

  11. Phase II- DCR

    Disease Control Rate

    Time frame: 3years

  12. Phase II- DoR

    Duration of Response

    Time frame: 3years

  13. Phase II- TTR

    Time to Response

    Time frame: 3years

  14. Phase II-ORR

    Overall Response Rate

    Time frame: 3years

  15. Phase II- OS

    Overall Survival

    Time frame: 3years

  16. Phase II- TEAE

    Treatment-Emergent Adverse Event

    Time frame: 3years

  17. Phase II- SAE

    Serious Adverse Event

    Time frame: 3years

  18. Phase II-PK:plasma concentration of Paclitaxel, DOTAP, Enlonstobart

    Pharmacokinetics:plasma concentration of Paclitaxel, DOTAP, Enlonstobart

    Time frame: 3years

  19. Phase II- ADA

    Anti-Drug Antibodies

    Time frame: 3years

  20. Phase II- Nab

    Neutralizing Anti-Drug Antibodies

    Time frame: 3years

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2025; primary completion for Jun 2028, 30 months later.

Of 72 industry-sponsored phase 1/2 interventional studies under Carcinoma, Hepatocellular, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 74. This study's planned 30 months is below that.

Counting every sponsor, half of 136 studies reached it within 53 months; a quarter within 38 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 21, 2025
First posted
Dec 15, 2025
StartEst.
Dec 23, 2025
Primary completionEst.
Jun 26, 2028
CompletionEst.
Feb 3, 2029
Last update
Dec 15, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 15, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07282509
Responsible party
Sponsor
First posted
Dec 15, 2025
Start date
Dec 23, 2025 (estimated)
Primary completion
Jun 26, 2028 (estimated)
Completion
Feb 3, 2029 (estimated)
Last update
Dec 15, 2025

Study contacts

Clinical Trials Information Group officer
Contact
ctr-contact@cspc.cn
86-0311-69085587

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion